» Articles » PMID: 38377788

Gut Microbiome, Short-chain Fatty Acids, Alpha-synuclein, Neuroinflammation, and ROS/RNS: Relevance to Parkinson's Disease and Therapeutic Implications

Overview
Journal Redox Biol
Date 2024 Feb 20
PMID 38377788
Authors
Affiliations
Soon will be listed here.
Abstract

In this review, we explore how short-chain fatty acids (SCFAs) produced by the gut microbiome affect Parkinson's disease (PD) through their modulatory interactions with alpha-synuclein, neuroinflammation, and oxidative stress mediated by reactive oxygen and nitrogen species (ROS/RNS). In particular, SCFAs-such as acetate, propionate, and butyrate-are involved in gut-brain communication and can modulate alpha-synuclein aggregation, a hallmark of PD. The gut microbiome of patients with PD has lower levels of SCFAs than healthy individuals. Probiotics may be a potential strategy to restore SCFAs and alleviate PD symptoms, but the underlying mechanisms are not fully understood. Also in this review, we discuss how alpha-synuclein, present in the guts and brains of patients with PD, may induce neuroinflammation and oxidative stress via ROS/RNS. Alpha-synuclein is considered an early biomarker for PD and may link the gut-brain axis to the disease pathogenesis. Therefore, elucidating the role of SCFAs in the gut microbiome and their impact on alpha-synuclein-induced neuroinflammation in microglia and on ROS/RNS is crucial in PD pathogenesis and treatment.

Citing Articles

Akkermansia muciniphila Akk11 Supplementation Attenuates MPTP-Induced Neurodegeneration by Inhibiting Microglial NLRP3 Inflammasome.

Wang W, Shi S, Su M, Li Y, Yao X, Jiang J Probiotics Antimicrob Proteins. 2025; .

PMID: 40048129 DOI: 10.1007/s12602-025-10499-1.


Association between plasma short-chain fatty acids and inflammation in human immunodeficiency virus-associated neurocognitive disorder: a pilot study.

Chen X, Wei J, Zhang L, Wang H, Zhang Y, Li Z Lipids Health Dis. 2025; 24(1):66.

PMID: 39984934 PMC: 11846350. DOI: 10.1186/s12944-025-02477-x.


The dual role of PGAM5 in inflammation.

Qi Y, Rajbanshi B, Hao R, Dang Y, Xu C, Lu W Exp Mol Med. 2025; 57(2):298-311.

PMID: 39930129 PMC: 11873181. DOI: 10.1038/s12276-025-01391-7.


Transcutaneous vagus nerve stimulation for Parkinson's disease: a systematic review and meta-analysis.

Shan J, Li Z, Ji M, Zhang M, Zhang C, Zhu Y Front Aging Neurosci. 2025; 16:1498176.

PMID: 39877075 PMC: 11772336. DOI: 10.3389/fnagi.2024.1498176.


Microbiome-based therapies for Parkinson's disease.

Alam M, Abbas K, Mustafa M, Usmani N, Habib S Front Nutr. 2024; 11:1496616.

PMID: 39568727 PMC: 11576319. DOI: 10.3389/fnut.2024.1496616.